As of September 30, 2025, the Company had cash, cash equivalents and marketable securities of $391.7 million, which includes proceeds from its upsized public offering. Based on its current operating plan, management expects the combined cash and marketable securities balance to fund operations into 2029.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX:
- DraftKings, Flutter downgraded: Wall Street’s top analyst calls
- 3 Best Stocks to Buy Now, 11/4/2025, According to Top Analysts
- Buy Rating for MBX Biosciences Driven by Promising PEP Platform and Successful Phase II Trials
- MBX Biosciences initiated with a Buy at TD Cowen
- MBX Biosciences Advances Phase 2a Study on PBH Treatment with Imapextide